Trial Profile
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms ENLIGHTEN-1
- Sponsors Alkermes plc
- 08 Apr 2024 According to Alkermes plc media release , company announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS), which took place April 3-7, 2024 in Florence, Italy.
- 03 Jan 2024 According to Alkermes plc media release, topline result is announced
- 01 Jun 2021 According to Alkermes plc media release, the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan) for the treatment of adults with schizophrenia results from this study are included in the approved labeling for LYBALVI.